Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing

Q: How long will it take to read this news story?

The story "Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing" has 311 words across 7 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing" was covered 19 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 261 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22725395</li><li>URL: https://beamstart.com/news/biocon-inks-licensing-supply-pact-17273555875740</li></ul>

Business Standard Logo Business Standard 19h ago

Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing - Business Standard

Quick Summary:

Under the agreement, the company will develop and manufacture the products and Tabuk Pharmaceuticals -- a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, will hold the marketing authorisation rights, and be responsible to register, import and promote them in the region, Biocon said in a regulatory filing.

Biocon Ltd on Thursday said it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its 'GLP-1' products for treating diabetes and chronic weight management in select countries of the Middle East.

The agreement also provides for a provision to expand to other 'GLP' products, as well as the option of a tech transfer that will enable localised manufacturing at a later stage, it added.